Search for content, post, videos

Cantargia receives patent approval in China

The Chinese patent office, the State Intellectual Property Office, has formally approved the company's patent application for IL1RAP as target molecule for antibody therapy of several types of solid tumours. Cantargia is developing antibodies against IL1RAP for treatment of life-threatening disea
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.